CJC-1295 - With DAC (5 mg) is a synthetic peptide analog derived from the biologically active portion of growth hormone–releasing hormone (GHRH). The peptide includes structural modifications and a Drug Affinity Complex (DAC) attachment designed to influence peptide stability and binding properties in experimental systems. The sequence contains 30 amino acids, including a terminal Lys(Mpa)-NH₂ modification that forms part of the DAC structure used in research variants of this peptide.

It is supplied as lyophilized powder in a sealed research-grade vial for laboratory studies examining endocrine signaling, peptide-mediated hormone regulation, and metabolic communication systems.

CJC-1295 - With DAC (5mg) Key Features & Specs

• Subcategory: Hormonal & Growth Signaling Research Peptides
• Strength: 5 mg
• CAS: 863288-34-0
• Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight:2 g/mol
• Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Mpa)-NH₂
• Synonyms: CJC1295, CJC-1295 with DAC

For laboratory research use only.

CJC-1295 - With DAC (5mg) Research Uses

CJC-1295 - With DAC (5mg) has been studied in laboratory environments investigating hormonal signaling and endocrine system regulation. Peptides derived from growth hormone–releasing hormone fragments are commonly examined in research models exploring communication between the hypothalamus and the pituitary gland.

Research involving peptides of this class typically focuses on biological systems such as metabolic regulation, endocrine signaling networks, and hormone-mediated cellular communication. These studies aim to understand how regulatory peptides may influence signaling pathways involved in endocrine control mechanisms.

In controlled research settings, investigators explore how modified GHRH peptides may interact with intracellular signaling pathways that regulate hormone signaling within metabolic and endocrine tissues.

CJC-1295 - With DAC (5mg) Insights & Observed Findings

Research involving GHRH-derived peptides such as CJC-1295 - With DAC has primarily been conducted in preclinical laboratory models, including cell culture experiments and experimental animal studies. In vitro investigations commonly evaluate peptide activity within nanomolar to micromolar concentration ranges, depending on the biological system being examined.

Animal studies examining endocrine signaling peptides have reported experimental dosing ranges in the microgram-per-kilogram (µg/kg) range. These experimental conditions vary depending on the research objective and the signaling mechanisms being studied.

Observed findings from peptide signaling research suggest that GHRH-derived peptides may influence molecular systems involved in hormonal communication and metabolic regulatory pathways. These observations remain part of ongoing scientific investigation and should not be interpreted as clinical outcomes.

CJC-1295 - With DAC (5mg) Handling & Storage

• Store under controlled laboratory conditions
• Refrigeration at 2–8 °C is recommended; –20 °C may be used for storage as appropriate
• Protect the lyophilized peptide from light, heat, and moisture to minimize degradation
• When reconstituted using sterile laboratory-grade solvent, store the resulting solution at 2–8 °C and use within the timeframe appropriate for the experimental protocol
• Avoid repeated freeze–thaw cycles, as they may affect peptide stability
• Researchers should use appropriate laboratory protective equipment and follow institutional biosafety guidelines when handling and disposing of the compound

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536